Evidence Snapshot

5-hydroxytryptamine receptor 1B

CHEMBL1898 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:11:28Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:11 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1898

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 1B as ChEMBL target CHEMBL1898, mapped to UniProt P28222. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

5-hydroxytryptamine receptor 1B

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL1898

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P28222

5-hydroxytryptamine receptor 1B

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5-hydroxytryptamine receptor 1B matters

As of 2026-09-13

5-hydroxytryptamine receptor 1B is reviewed as 5-hydroxytryptamine receptor 1B (UniProt P28222); 5-hydroxytryptamine receptor 1B shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 32 approved drugs, 2294 compounds, and 558 assays, with lead potency reaching pChEMBL 10.1.

Protein context

5-hydroxytryptamine receptor 1B

5-hydroxytryptamine receptor 1B Sequence length is 390 aa.

Review this target as 5-hydroxytryptamine receptor 1B, mapped to UniProt P28222. Sequence length is 390 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P28222 Protein

Disease context

migraine disorder

5-hydroxytryptamine receptor 1B shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALMOTRIPTAN MALATE, ELETRIPTAN HYDROBROMIDE, FROVATRIPTAN SUCCINATE.

Start review with migraine disorder because it currently carries approved-linked support. Linked drugs include ALMOTRIPTAN MALATE, ELETRIPTAN HYDROBROMIDE, FROVATRIPTAN SUCCINATE, NARATRIPTAN HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 8 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 32 approved drugs, 2294 compounds, and 558 assays for this target. The dominant activity type is KI. CHEMBL144397 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL144397 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine

32 approved pChEMBL 10.1

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 1B matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P28222, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why migraine disorder is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2294

Total Compounds

558

Total Assays

Approved Drugs

IC50: 383.0, KI: 1328.0, EC50: 102.0, KD: 8.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL144397	10.1	EC50	—
No preferred name CHEMBL342323	10.0	EC50	—
No preferred name CHEMBL374973	10.0	Ki	—
No preferred name CHEMBL438619	10.0	Ki	—
No preferred name CHEMBL144030	10.0	Ki	—

Approved Drugs

Structure	Compound	First Approval
	CARIPRAZINE HYDROCHLORIDE CHEMBL2024517	2015
	BREXPIPRAZOLE CHEMBL2105760	2015
	SILODOSIN CHEMBL24778	2008
	PALIPERIDONE CHEMBL1621	2006
	ARIPIPRAZOLE CHEMBL1112	2002
	ELETRIPTAN CHEMBL1510	2002
	FROVATRIPTAN CHEMBL1279	2001
	FROVATRIPTAN SUCCINATE CHEMBL2138684	2001
	NARATRIPTAN CHEMBL1278	1998
	RIZATRIPTAN CHEMBL905	1998
	ZOLMITRIPTAN CHEMBL1185	1997
	SERTINDOLE CHEMBL12713	1996
	OLANZAPINE CHEMBL715	1996
	NEFAZODONE HYDROCHLORIDE CHEMBL1200492	1994
	RISPERIDONE CHEMBL85	1993
	SUMATRIPTAN CHEMBL128	1992
	CLOZAPINE CHEMBL42	1989
	OXYMETAZOLINE CHEMBL762	1986
	ERGOTAMINE CHEMBL442	1948
	DIHYDROERGOTAMINE MESYLATE CHEMBL1200517	1946

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:11:28Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:11 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1898